[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100642613":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":15,"centralContacts":19,"locations":25,"responsibleParty":129,"collaborators":10,"id":131,"slug":10,"hasResults":132,"nctId":133,"briefTitle":134,"officialTitle":135,"acronym":136,"eligibilityCriteria":137,"healthyVolunteers":132,"sex":138,"minAge":10,"maxAge":10,"enrollmentInfo":139,"targetDuration":10,"studyType":142,"phases":10,"briefSummary":143,"conditions":144,"keywords":152,"overallStatus":28,"whyStopped":10,"lastUpdateSubmitDate":158,"lastUpdatePostDateStruct":159,"startDateStruct":162,"completionDateStruct":164,"leadSponsor":166,"locationsCount":167},{"fullName":5,"class":6},"BillionToOne Inc.","INDUSTRY",[8,12],{"label":9,"type":10,"description":11,"interventionNames":10},"High Risk",null,"Pregnant individuals between 10 and 20 weeks of gestation with singleton pregnancies and who have a clinical indication for CFC testing, such as high-risk cfDNA results for common aneuploidies, copy number variants including 22q11.2, or sex chromosome aneuploidies",{"label":13,"type":10,"description":14,"interventionNames":10},"General Risk","Pregnant individuals between 10 and 20 weeks of gestation with singleton pregnancies (excluding gestational surrogates) who do not have a clinical indication for CFC and are undergoing prenatal diagnostic testing",[16],{"name":17,"affiliation":5,"role":18},"Julia Wynn, MS, MS, CGC","PRINCIPAL_INVESTIGATOR",[20],{"name":21,"role":22,"phone":23,"phoneExt":10,"email":24},"Shannon O'Rourke Senior Research Manager, MS, CGC","CONTACT","650-460-2551","unityregistry@billiontoone.com",[26,46,62,79,96,113],{"facility":27,"status":28,"city":29,"state":30,"zip":31,"country":32,"cosmosGeoPoint":33,"geoPoint":38,"contacts":39},"Valley Perinatal Services","RECRUITING","Phoenix","Arizona","85004","United States",{"type":34,"coordinates":35},"Point",[36,37],-112.07404,33.44838,{"lat":37,"lon":36},[40,44],{"name":41,"role":22,"phone":42,"phoneExt":10,"email":43},"Research Department","480-756-6000","research@valleyperinatal.com",{"name":45,"role":18,"phone":10,"phoneExt":10,"email":10},"Nayo Williams, MD",{"facility":47,"status":28,"city":48,"state":49,"zip":50,"country":32,"cosmosGeoPoint":51,"geoPoint":55,"contacts":56},"San Gabriel Valley Perinatal Medical Group","West Covina","California","91710",{"type":34,"coordinates":52},[53,54],-117.93895,34.06862,{"lat":54,"lon":53},[57,61],{"name":58,"role":22,"phone":59,"phoneExt":10,"email":60},"Richard Burwick, MD","(626) 337-4425","dr.burwick@sgvpmg.com",{"name":58,"role":18,"phone":10,"phoneExt":10,"email":10},{"facility":63,"status":28,"city":64,"state":65,"zip":66,"country":32,"cosmosGeoPoint":67,"geoPoint":71,"contacts":72},"Sarasota Memorial Health Care System","Sarasota","Florida","34239",{"type":34,"coordinates":68},[69,70],-82.53065,27.33643,{"lat":70,"lon":69},[73,77],{"name":74,"role":22,"phone":75,"phoneExt":10,"email":76},"Scarleth Andino-Funez, BSN, RN","941-917-2627","Scarleth-AndinoFunez@smh.com",{"name":78,"role":18,"phone":10,"phoneExt":10,"email":10},"Larry C Matsumoto, MD",{"facility":80,"status":28,"city":81,"state":82,"zip":83,"country":32,"cosmosGeoPoint":84,"geoPoint":88,"contacts":89},"Pediatrix Medical Group of Georgia","Atlanta","Georgia","30342",{"type":34,"coordinates":85},[86,87],-84.38798,33.749,{"lat":87,"lon":86},[90,94],{"name":91,"role":22,"phone":92,"phoneExt":10,"email":93},"Deena Yowler, NP, CNM","404-847-1592","deena.yowler@pediatrix.com",{"name":95,"role":18,"phone":10,"phoneExt":10,"email":10},"Gretchen Koontz, MD",{"facility":97,"status":28,"city":98,"state":99,"zip":100,"country":32,"cosmosGeoPoint":101,"geoPoint":105,"contacts":106},"Woman's Hospital","Baton Rouge","Louisiana","70817",{"type":34,"coordinates":102},[103,104],-91.18747,30.44332,{"lat":104,"lon":103},[107,111],{"name":108,"role":22,"phone":109,"phoneExt":10,"email":110},"Bri Jones, MPH","225-927-1300","Briasha.Jones@womans.org",{"name":112,"role":18,"phone":10,"phoneExt":10,"email":10},"Elizabeth Sutton, PhD",{"facility":114,"status":28,"city":115,"state":116,"zip":117,"country":32,"cosmosGeoPoint":118,"geoPoint":122,"contacts":123},"Pediatrix Medical Group","Houston","Texas","773339",{"type":34,"coordinates":119},[120,121],-95.36327,29.76328,{"lat":121,"lon":120},[124,128],{"name":125,"role":22,"phone":126,"phoneExt":10,"email":127},"Olaide Ashimi Balogun, MD","346-616-2777","olaide.ashimibalogun@pediatrix.com",{"name":125,"role":22,"phone":10,"phoneExt":10,"email":10},{"type":130,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100642613",false,"NCT07643896","The ADVANCE (Assay Development and Validation for Pre-Natal and Obstetric Conditions) Study is the Largest U.S.-Based Prospective Study Demonstrating a Circulating Fetal Cell (CFC) Based Approach to Non-invasive Fetal Risk Assessment","ADVANCE Study: Assay Development and Validation for Pre-Natal and Obstetric Conditions","ADVANCE","Inclusion Criteria:\n\n* pregnant individuals between 10 and 20 weeks of gestation\n* singleton gestation\n\nExclusion Criteria:\n\n\\- active cancer","FEMALE",{"count":140,"type":141},1000,"ESTIMATED","OBSERVATIONAL","The goal of the ADVANCE (Assay Development and Validation for Pre-Natal and Obstetric Conditions) study is to compare the concordance of results of a novel non-invasive circulating fetal cell (CFC) assay to the results of prenatal invasive diagnostic testing or postnatal genetic and clinical diagnosis of the resulting neonate. This is a prospective study of pregnant individuals.",[145,146,147,148,149,150,151],"Pregnant Individuals","Aneuploidy","Down Syndrome (Trisomy 21)","22q11.2 Deletion Syndrome","Trisomy 13","Trisomy 18","Sex Chromosome Abnormalities",[153,154,155,156,157],"pregnant","aneuploidy","NIPT","NIPS","circulating fetal cell","2026-06-10",{"date":160,"type":161},"2026-06-12","ACTUAL",{"date":163,"type":161},"2026-01-10",{"date":165,"type":141},"2028-06",{"name":5,"class":6},6]